2. Metabolic Enzyme/Protease Apoptosis
  3. Carbonic Anhydrase Apoptosis
  4. Zonisamide

Zonisamide  (Synonyms: AD 810; CI 912)

Cat. No.: HY-B0124 Purity: 99.94%
COA Handling Instructions

Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy.

For research use only. We do not sell to patients.

Zonisamide Chemical Structure

Zonisamide Chemical Structure

CAS No. : 68291-97-4

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 113 In-stock
Solution
10 mM * 1 mL in DMSO USD 113 In-stock
Solid
200 mg USD 103 In-stock
500 mg USD 163 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Zonisamide:

Zonisamide Related Antibodies

Top Publications Citing Use of Products

View All Carbonic Anhydrase Isoform Specific Products:

View All Isoforms
CA I CA Ⅱ CA Ⅸ CA XII

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy[1][2][3][4].

IC50 & Target

CA Ⅱ

 

In Vitro

Zonisamide (10, 50, 100, 200 μM; 24 h) increases viability of SH-SY5Y cells via an anti-apoptotic effect[1].
? Zonisamide (100 μM; 24 h) shows neuroprotective effects in PD-cellular models. (PD: parkinson’s disease)[1].
? Zonisamide (100 μM; 24 h) reduces levels of proapoptotic molecules, and upregulates levels of MnSOD (MnSOD over-expression attenuates MPTP toxicity and protects cells from apoptosis)[1].
? Zonisamide (0.1, 0.3, 1 μM; 24 h) inhibits cardiac hypertrophy and fibrosis in vitro[3].
? Zonisamide markedly increases the expression of Hrd1 in Ang II-treated NRCMs[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Zonisamide Related Antibodies

Cell Viability Assay[1]

Cell Line: SH-SY5Y cells
Concentration: 10, 50, 100, 200 µM
Incubation Time: 24 h
Result: Induced an increase of cell viability, and with the greatest effect being at 100 µM.
Exhibited neuroprotective effect on SH-SY5Y cells (PD-cellular models) when at 100 µM.

Apoptosis Analysis[1]

Cell Line: SH-SY5Y cells
Concentration: 100 µM
Incubation Time: 24 h
Result: Showed an effect of anti-apoptotic.

RT-PCR[3]

Cell Line: NRCMs and cardiac fibroblasts (expose to Ang II for cardiomyocyte hypertrophy and fibrosis model)
Concentration: 0.1, 0.3, 1 μM
Incubation Time: 24 h
Result: Decreased the expression of atrial natriuretic factor (ANF) and cardiomyosin heavy chain β (β-MHC) but increased the expression of cardiac myosin heavy chain α (α-MHC) in NRCMs.
Decreased cardiac expression of the fibrosis-related gene Collagen 1A1 (Col1A1) in cardiac fibroblasts.

Western Blot Analysis[1]

Cell Line: SH-SY5Y cells
Concentration: 100 µM
Incubation Time: 24 h
Result: Reduced the proapoptotic molecules levels of cleaved caspase-9, -3, and p-JNK, and blocked the activation of proapoptotic molecules in SH-SY5Y cells. Induced an increase in MnSOD levels.(MnSOD over-expression attenuates MPTP toxicity and protects cells from apoptosis).
In Vivo

Zonisamide (40 mg/kg; i.p.; single daily for 14 days) prevents seizures in FeCl3-induced chronic amygdalar seizures model[2].
? Zonisamide (14, 28, 56 mg/kg; i.p.; single daily for 6 weeks) alleviates cardiac hypertrophy and improved cardiac function in rats subjected to AAC (abdominal aortic constriction)[3].
? Zonisamide (14, 28, 56 mg/kg; i.p.; single daily for 6 weeks) upregulates Hrd1 expression and accelerates ERAD in the hearts of AAC rats[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Wistar rats (200-250 g; FeCl3-induced chronic amygdalar seizures)[2].
Dosage: 40 mg/kg
Administration: Intraperitoneal injection; single daily for 14 days.
Result: Showed activity of anti-seizures.
Significantly down-regulated GABA transporters GAT-1 in the hippocampus.
Animal Model: Adult male Sprague-Dawley rats (100-120 g; cardiac hypertrophy model)[3].
Dosage: 14, 28, 56 mg/kg
Administration: Intraperitoneal injection; single daily for 6 weeks.
Result: Significantly attenuated cardiac hypertrophy and fibrosis.
Increased LV ejection fraction (EF), fractional shortening (FS) and E/A ratio.
Markedly increased the expression of Hrd1 in the hearts of AAC rats.
Clinical Trial
Molecular Weight

212.23

Appearance

Solid

Formula

C8H8N2O3S
CAS No.
SMILES

O=S(CC1=NOC2=C1C=CC=C2)(N)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 250 mg/mL (1177.97 mM; Need ultrasonic)

H2O : 0.67 mg/mL (3.16 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.7119 mL 23.5593 mL 47.1187 mL
5 mM 0.9424 mL 4.7119 mL 9.4237 mL
10 mM 0.4712 mL 2.3559 mL 4.7119 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (9.80 mM); Clear solution

  • 2.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (9.80 mM); Clear solution

  • 3.

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.08 mg/mL (9.80 mM); Clear solution

  • 4.

    Add each solvent one by one:  PBS

    Solubility: 1 mg/mL (4.71 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

*All of the co-solvents are available by MedChemExpress (MCE).
Purity & Documentation

Purity: 99.94%

COA (252 KB) HNMR (240 KB) LCMS (245 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Zonisamide Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

Zonisamide68291-97-4AD 810 CI 912AD810AD-810CI912CI 912CI-912Carbonic AnhydraseApoptosisCarbonate dehydrataseparkinson’s diseaseseizureepilepsySH-SY5YNRCMscardiac fibroblastscardiac hypertrophyInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Zonisamide
Cat. No.:
HY-B0124
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.